Evidence map›Paper›PMID 35804900›Full record

ArticleCancers2022

CD73 Promotes Chronic Lymphocytic Leukemia.

David Allard, Pavel Chrobak, Yacine Bareche, Bertrand Allard, Priscilla Tessier, Marjorie A Bergeron, Nathalie A Johnson, John Stagg

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

David AllardCentre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 0A9, Canada.ORCID 0000-0001-8820-8161
Pavel ChrobakCentre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 0A9, Canada.
Yacine BarecheCentre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 0A9, Canada.ORCID 0000-0002-7208-6494
Bertrand AllardCentre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 0A9, Canada.
Priscilla TessierCentre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 0A9, Canada.
Marjorie A BergeronCentre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 0A9, Canada.
Nathalie A JohnsonDepartment of Medicine, Jewish General Hospital, Montréal, QC H3T 1E2, Canada.
John StaggCentre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 0A9, Canada.
Centre Hospitalier de l’Université de Montréal · CAJewish General Hospital · CA

Funding

Leukemia and Lymphoma Society of Canada
6 · The paper itself

Abstract

The ecto-nucleotidase CD73 is an important immune checkpoint in tumor immunity that cooperates with CD39 to hydrolyze pro-inflammatory extracellular ATP into immunosuppressive adenosine. While the role of CD73 in immune evasion of solid cancers is well established, its role in leukemia remains unclear. To investigate the role of CD73 in the pathogenesis of chronic lymphocytic leukemia (CLL), Eµ-TCL1 transgenic mice that spontaneously develop CLL were crossed with CD73

Indexed as

adenosineCD73chronic lymphocytic leukemiaPD-L1

Identifiers

PMID35804900
PMCPMC9264813
OpenAlexW4283516356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.